Gerber, Hans-Peter <br/><br/>
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.  [electronic resource] 

 -  Blood  Apr 2009 
 - 4352-61 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2008-09-179143  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antigens, CD19--immunology<br/>Antineoplastic Agents--therapeutic use<br/>Blotting, Western<br/>Cell Line, Tumor<br/>Cell Survival<br/>Citrulline--chemistry<br/>Dimerization<br/>Dipeptides--metabolism<br/>Drug Resistance, Neoplasm<br/>Female<br/>Flow Cytometry<br/>Gene Dosage<br/>Humans<br/>Immunoconjugates--therapeutic use<br/>Immunoenzyme Techniques<br/>Lymphoma, Non-Hodgkin--drug therapy<br/>Lysosomes<br/>Mice<br/>Mice, SCID<br/>Oligopeptides--metabolism<br/>Receptors, Complement 3d--genetics<br/>Rituximab<br/>Valine--chemistry<br/>Xenograft Model Antitumor Assays